FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-028							
Estimated average burden							
hours per response:	0.5						

STATEMENT	OF CHANGES	S IN BENEFICIAL	OWNERSHIP

Instruc	tion 1(b).			Filed		nt to Sectio ction 30(h)						1934					
1. Name and Address of Reporting Person [*] Goel Shubh				2. Issuer Name and Ticker or Trading Symbol <u>FENNEC PHARMACEUTICALS INC.</u> [FENC]						(Ch	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title Other (specify						
(Last)	(F	irst)	(Middle)		3. Date of Earliest Transaction (Month/Day/Year)						⁻	X Onlet (give title Other (specify below) below) Chief Commercial Officer					
68 TW ALEXANDER DRIVE, PO BOX 13628				3	06/02/2021							Chi	er Comm	ercia	Officer		
(Street)	M N	С	27709		4. If Amendment, Date of Original Filed (Month/Day/Year)					Line	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person						
(City)	(S	tate)	(Zip)		Form filed by More than One Reporting Person								ing				
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																
Date				2. Transa Date (Month/Da	Execution Date,			Code (Instr.			5. Amour Securitie Beneficia Owned F Reported	es For ally (D) following (I) (rm: Direct) or Indirect (Instr. 4)	7. Nature of Indirect Beneficial Ownership		
						Code	v	Amount	(A) ((D)	Price	Transacti (Instr. 3 a	ction(s)			Instr. 4)		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	conversion Date r Exercise (Month/Day/Year) rice of verivative			isactior e (Instr	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Expiration Date (Month/Day/Year)		7. Title and Amoun of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported	ly Ownership Form: Direct (D) or Indirect (I) (Instr. 4	Ownership Form:	Beneficial Ownership (Instr. 4)	
				Cod	e V	(A)	(D)	Date Exercisabl		Expiration Date	Title	Amount or Number of Shares		Transaction((Instr. 4)			
Stock Option (right to buy) ⁽¹⁾	\$7.53	06/02/2021		A		100,000		(2)	0	6/02/2031	Common Shares	100,000	\$0	100,00	0	D	
Explanation	n of Respons	Ses:															

1. On June 3, 2021, Fennec Pharmaceuticals, Inc. announced that Shubh Goel was granted an incentive stock option to purchase 100,000 shares of the Issuer's common shares pursuant to the Issuer's 2020 Equity Incentive Plan. The date of the grant is June 2, 2021.

2. 1/3 of the shares subject to this option shall vest immediately and may be exercised as of June 2, 2022 (the "Vesting Commencement Date"). 1/24 of the shares subject to this option shall vest immediately and may be exercised as of the last day of each month following the Vesting Commencement Date. As of May 31, 2024 and thereafter, 100% of the total number of shares subject to this option shall be vested.

/s/ Shubh Goel, Chief **Commercial Officer**

06/03/2021

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.